The fact
This disconnect between valuation and biotech fundamentals raises questions among sector analysts.
Investors are examining whether this gap represents an opportunity or correction risk.
Click the link to read an article on the topic:
This disconnect between valuation and biotech fundamentals raises questions among sector analysts.
Investors are examining whether this gap represents an opportunity or correction risk.